New study showed the impact of gastrointestinal disorders in patients with Parkinson’s disease

• New data from a retrospective cohort study presented at major movement disorder congress

Brussels (Belgium), 15th June 2010, 1430 CET – New data from a retrospective cohort study showed that up to three quarters of patients with Parkinson’s disease (PD) developed gastrointestinal disorders (GID) that can have a substantial adverse effect on major PD-related clinical and health economic outcomes. These data were presented at the 14th International Congress of Parkinson’s Disease and Movement Disorders in Buenos Aires, Argentina (June 13-17, 2010).

“The new retrospective cohort study suggested that the prevalence of gastrointestinal disorders among patients with Parkinson’s disease was high, increased over time and had a significant impact on clinical and societal outcomes.” said Dr. Florent Richy, Head of Epidemiology, UCB & Adjunct Professor of Epidemiology, University of Liège, Belgium. “Gastrointestinal disorders can impair the onset of symptom relief by Parkinson’s disease drugs and these data help us to better understand the prevalence and consequences of such disorders amongst patients diagnosed with Parkinson’s disease.”

The study found that gastrointestinal disorders in PD patients were associated with significantly higher rates of neuropsychiatric and motor disorders, as well as increased emergency room admissions, number of concurrent drugs and non-PD healthcare costs.

About the Study
The new findings came from a two year matched retrospective cohort study performed on a U.S. database of patient records (Pharmetrics®)* which included demographic, diagnostic, procedural and prescription information. Patients with at least two prior diagnoses of Parkinson’s disease and continuous prescriptions of levodopa or dopamine agonists between 1st September 2005 and 1st September 2006 were selected, and health outcomes and health utilization patterns were followed up over a two-year period.
Outcomes were defined on the basis of a literature review and included neuropsychiatric, motor, urogenital disturbances, healthcare utilization and related costs.

Four hundred and eighty five patients with Parkinson’s disease and GID were matched with 485 patients with Parkinson’s disease and without GID. In the data cut, GID incidence among patients with Parkinson’s disease and no history of GID increased over time, stabilizing at 75% at 92 months. In addition, GID was associated with significantly higher rates of neuropsychiatric and motor disorders, including psychosexual dysfunction (RR=8, p=0.05), anxiety (RR=1.61, p<0.01), depression (RR=1.28, p=0.03), ataxia (RR=1.24, p=0.03), pain (RR=1.29, p<0.01), movement disorders (RR=1.39, p=0.02), urinary incontinence (RR=1.43, p=0.01) and risk of fall (RR=1.44, p=0.03). Emergency room admissions (ratio =1.42, p<0.01), number of concurrent drugs (ratio=1.06, p=0.04) and Parkinson’s disease and non-Parkinson’s disease healthcare costs (ratios =1.13 and 1.12, p<0.01 respectively) increased during the observation period in the GID patients.

* This study was performed using a licensed IMS Pharmetrics® data cut

**For further information**

Eimear O Brien, Associate Director, Global CNS Communications  
T +32 2 559 9271, eimear.obrien@ucb.com

Andrea Levin / Public Relations Manager, CNS, UCB, Inc.  
Office: 770.970.8352 / Mobile: 404.483.7329 / Email: andrea.levin@ucb.com

**Reference**

Gastrointestinal disorders in patients with Parkinson’s disease: A double-edged sword  
Richy F1, Gunn A2, Makaroff L3, Gervasoni C4, Helmers S5  
1UCB Pharma SA, Brussels, Belgium & University of Liège, Belgium; 2UCB Pharma SA, Brussels, Belgium; 3Business & Development, Life Sciences, Brussels Belgium; 4Keyrus Biopharma, Lasne, Belgium; 5Emory University School of Medicine, Atlanta, US  
**Poster Session I, June 14th, 2010, 0900-1800. Presented at the 14th International Congress of Parkinson’s Disease and Movement Disorders in Buenos Aires, Argentina**

**About UCB**

UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9 000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).

**Forward looking statement**

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.